Boehringer Ingelheim and IBM collaborate to advance generative AI and foundation models for therapeutic antibody development Read more
AbbVie Announces FDA and EMA Updates for Epcoritamab (EPKINLY/TEPKINLY) for the Treatment of Relapsed/Refractory Follicular Lymphoma Read more
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Read more
European Commission Approves KAFTRIO in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5 Read more
SK bioscience and Hilleman Laboratories Announce Joint Development of Second-Generation Zaire Ebola Virus Vaccine Read more
Boehringer Ingelheim receives approval for SENVELGO in Europe: the first oral liquid medication for diabetic cats Read more
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma Read more
Vivodyne Announces $38 Million Seed Financing Led by Khosla Ventures to Develop Lab-Grown Human Organs Read more
FDA Grants Orphan Drug Designation to NeoImmuneTech’s NT-I7 for the Treatment of Acute Radiation Syndrome Read more
Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of RYBREVANT (amivantamab-vmjw) Plus Chemotherapy for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Progressed on or after Osimertinib Read more